French health tech company Keen Eye has launched a new artificial intelligence (AI) web-based platform to support organisations conducting clinical trials.

The computational pathology platform is Good Clinical Laboratory Practices (GCLP) compliant and will help in expediting clinical trials with deep learning-based image analysis. It will allow every actor in pathology to run digital image analysis efficiently.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The platform will address the safety of clinical trial subjects and ensure the integrity of study data. An audit trail also captures every action performed on the platform.

Keen Eye founder and CEO Sylvain Berlemont said: “It provides a quantum leap in performance while contributing to regulatory compliance, hence paving the way for better standards in clinical image analysis.

“We are proud to have developed the solution every pharma and CRO has been waiting for.”

Institut Gustave Roussy, France, former head of pathology Dr Jacques Bosq said: “As pathologists, we always put patients’ interests first. Keen Eye’s expertise in digital tissue analysis has proven to be a really effective solution.

“With this innovative GCLP-compliant platform, pathologists will be able to perform biomarker detection and quantification in clinical study protocols in a reliable, standardised and efficient manner.”

The company will demonstrate the platform’s capabilities during Oxford Global’s ‘Biomarkers UK’ event in November 2021.

Established in 2015, Keen Eye works to advance the use of AI for the benefit of biologists, pathologists and patients. The company also aims to support the development of new therapies with improved analytics.